FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)‐associated metastatic castrate‐resistant prostate cancer (mCRPC) who have been treated with androgen receptor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Anscher, Mitchell S., Chang, Elaine, Gao, Xin, Gong, Yutao, Weinstock, Chana, Bloomquist, Erik, Adeniyi, Oluseyi, Charlab, Rosane, Zimmerman, Sarah, Serlemitsos‐Day, Maritsa, Ning, Yang Min, Mayrosh, Ruth, Fuller, Barbara, Trentacosti, Ann Marie, Gallagher, Pamela, Bijwaard, Karen, Philip, Reena, Ghosh, Soma, Fahnbulleh, Frances, Diggs, Felicia, Arora, Shaily, Goldberg, Kirsten B., Tang, Shenghui, Amiri‐Kordestani, Laleh, Pazdur, Richard, Ibrahim, Amna, Beaver, Julia A.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2020
Témata:
Regulatory Issues: FDA
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873319/
https://ncbi.nlm.nih.gov/pubmed/33145877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13585
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky